A comprehensive testing platform for mechanical heart valves to propel innovation towards anticoagulant-independence
A comprehensive testing platform for mechanical heart valves to propel innovation towards anticoagulant-independence
批准号:
10592424
负责人:
Alessandro Bellofiore
金额:
$25.64万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-04-20 至 2025-03-31
关键词:
AddressAdultAdverse effectsAffectAgeAnticoagulant therapyAnticoagulantsArtificial HeartBioprosthesis deviceBloodBlood CirculationBlood PlateletsBlood coagulationBlood flowCharacteristicsChildChildhoodCirculationClinicalCoagulation ProcessCommunitiesDependenceDepositionDeveloping CountriesEducationEnvironment DesignExhibitsExposure toFDA approvedFutureGenerationsGoalsGrowthGuidelinesHeart ValvesImageIn VitroLasersLifeMeasurementMeasuresMechanicsOpticsOutcomePatientsPerformancePlatelet ActivationPlayPopulationPrognosisRecommendationRecording of previous eventsRepeat SurgeryResearchRestRoleStudentsSurfaceTestingThromboembolismThrombusTimeVelocimetriesWorkanalogaortic valve disorderaortic valve replacementblood damagedesigngraduate studenthealth care availabilityhemodynamicsimplantationimprovedin vivoindexinginnovationlow income countrymechanical loadnovelolder patientparticlepediatric patientsperformance testsprototypeshear stressthrombogenesisthrombotictime usetreatment strategyundergraduate studentunderrepresented minority studentyoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Patients needing aortic valve replacement are faced with a choice between mechanical heart valves (MHVs)
and bioprosthetic valves. For younger patients, MHVs are preferable because of their extreme durability, but
they become dependent on anticoagulant therapy for the rest of their life. There is a strong need to spark
innovation over the stagnant MHV design, which has not substantially changed in 40 years. The ultimate goal
is to usher in a new generation of MHVs that achieve complete independence from anticoagulants. The Pl's
long-term objective is to create and sustain a student-centered research environment for the design,
prototyping and testing of novel MHV design paradigms that improve valve hemodynamic performance and
reduce thrombogenicity. A substantial amount of work has already elucidated the importance of abnormal flow
features in triggering platelet activation, and thus blood clotting, near the hinges and the closing of MHVs. To
further advance the understanding of flow-induced blood clotting and identify anticoagulant-free MHV designs,
the PI will develop a MHV testing platform that accounts for the effect of clot deposits on blood flow near the
MHV and allows to reproduce comparable realistic flow conditions for both hemodynamic performance tests
(which require an optically-clear blood analog) and thrombogenicity tests (which require real blood). To achieve
that, the PI will combine a hydrodynamic tester for laser-based flow measurements and an unprecedented
MHV thrombogenicity tester based on blood circulation through MHVs in a pumpless closed loop.
The underlying hypothesis of this research is that, unlike with the pristine MHVs used for in-vitro and numerical
studies, the deposition of clot on the MHV that occurs in-vivo significantly affects blood flow features,
mechanical loading of platelets, and thrombus growth rate. Future MHV design strategies should consider the
fundamental hemodynamic changes occurring after MHV implantation. The specific aims of this study are:
Aim 1. Quantify the relationship between clot deposit extent, shear stress and platelet damage indices.
Aim 2. Investigate hemodynamics and thrombogenicity of trileaflet MHVs, compared to bileaflet MHVs.
Aim 3. Quantify the effect of valve size on flow velocities and shear stress near valve closure in MHVs.
This project will (1) establish an accurate platform for comprehensive MHV hemodynamics/thrombogenicity
testing that will propel innovation in the treatment of aortic valve disease; (2) demonstrate the role thrombus
deposits play in thrombus growth; (3) demonstrate the viability of trileaflet MHVs for adult and pediatric
populations. These outcomes lay the ground work for future research on anticoagulant-free MHVs that will
transform treatment options and prognosis for younger patients and patients from developing countries. For the
graduate and undergraduate students involved, including students from underrepresented minorities, this
project is a unique research and educational opportunity that will enrich them professionally and increase their
appeal to potential recruiters.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A comprehensive testing platform for mechanical heart valves to propel innovation towards anticoagulant-independence
-
批准号:10379306
-
项目类别:
-
资助金额:$29.3万
-
财政年份:2020
-
负责人:Alessandro Bellofiore
-
依托单位:
海外基金